Table 1.

Summary of aortic ring experiments

		Treatment*		Intervention
Experiment	Primary Measure(s)	Type	Dose	Drug or manipulation	Dose	Number of Rings Tested
Aortic rings treated with or without interventions before stimulation with increasing PE doses
Effect of pretreatment with diluent, PA, or ET	MCF and EC50	Diluent				8
		PA	1,600			9
		ET	800†			7
Effect of pretreatment with differing doses of ET	MCF and EC50	PA				5
		ET	50			1
		ET	100			3
		ET	200			5
		ET	400			5
		ET	800			3
Effect of PA mAb on ET pretreatment	MCF and EC50	PA	1,600	PA mAb	10ׇ	10
		PA	1,600	NS mAb		10
		ET	800	PA mAb	10×	12
		ET	800	NS mAb		12
Effect of adefovir on ET pretreatment	MCF and EC50	PA	1,600	Diluent		4
		PA	1,600	Adefovir	1.6 μM	4
		ET	800	Diluent		12
		ET	800	Adefovir	1.6 μM	12
Effect of ET pretreatment comparing intact and denuded aortic rings	MCF and EC50	PA	1,600	Intact ring		8
		ET	800	Intact ring		8
		PA	1,600	Denuded ring		8
		ET	800	Denuded ring		8
Effect of pretreatment with differing doses of LT	MCF and EC50	PA				5
		LT	40			1
		LT	80			5
		LT	160			5
		LT	320			5
		LT	640			1
Aortic rings treated with or without intervention after contraction with a single dose of PE
Effect of ET with differing doses of PE precontraction	Percent relaxation
1 μM PE		PA	1,600			11
		ET	800			9
10 μM PE		PA	1,600			4
		ET	800			4
100 μM PE		PA	1,600			2
		ET	800			2
Effect of ET comparing intact and denuded aortic rings	Percent relaxation	PA	1,600	Intact ring		6
		ET	800	Intact ring		6
		PA	1,600	Denuded ring		5
		ET	800	Denuded ring		5

PE, phenylephrine; ET, edema toxin; MCF, maximal contraction during the PE dose response; EC₅₀, dose of PE producing 50% of maximum contraction; PA, protective antigen; NS mAb, nonspecific (control) monoclonal antibody; PA mAb, PA-directed mAb; LT, lethal toxin.

^*Treatment was either before (i.e., pretreatment) or after stimulation with PE.

^†Dose of ET shown represents the amount of edema factor administered (see materials and methods).

^‡Dose of PA mAb represents 10× the PA molar dose, whereas the dose of NS mAb used had the same protein content as PA mAb.